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INTRODUCTION {#ped412101-sec-0001}
============

The phosphatidylinositol‐4,5‐bisphosphate 3‐kinase, catalytic subunit delta gene (*PIK3CD*), associated with primary immunodeficiency disease (PID), encodes the p110δ catalytic subunit and is predominantly expressed in immune cells such as lymphocytes. The p110δ together with the p85α regulatory subunit form the heterodimeric lipid kinase PI3Kδ, which regulates immune cell metabolism, survival, proliferation, and function through the phosphoinositide 3‐kinase (PI3K)‐AKT‐mammalian target of rapamycin signaling pathway.[1](#ped412101-bib-0001){ref-type="ref"} Several studies have confirmed that a p110δ deletion is strongly associated with the occurrence of many immune diseases, such as inflammatory bowel disease.[2](#ped412101-bib-0002){ref-type="ref"}, [3](#ped412101-bib-0003){ref-type="ref"} Moreover, Angulo et al showed that the gain of function (GOF) *PIK3CD* mutation induced p110δ‐activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency (PASLI) disease through defects in the immune function of T and B cells.[4](#ped412101-bib-0004){ref-type="ref"} PASLI is also known as activated PI3K δ syndrome (APDS). Hartman et al reported that the same mutation in *PIK3CD* could also trigger primary sclerosing cholangitis (PSC).[5](#ped412101-bib-0005){ref-type="ref"}

Currently, fewer than 100 cases with *PIK3CD* mutations have been reported worldwide, mainly association with PASLI, and the major mutation site is E1021K. In this study, we retrospectively summarized the data of four children from our hospital with *PIK3CD* mutations, and analyzed their clinical characteristics, genotypes, treatments, and prognoses to improve the knowledge of *PIK3CD* mutations and related diseases.

CASE REPORT {#ped412101-sec-0002}
===========

Mutation analysis {#ped412101-sec-0003}
-----------------

Four patients were enrolled in our study. Three were male and one was female, with a mean age at diagnosis of 3.98 years (range, 0.6--8.4 years). The four children came from four unrelated Chinese families with no family history of genetic disease. The whole exome sequencing was performed by the second‐generation sequencing technology. All children were shown to carry a dominantly inherited *PIK3CD* heterozygous mutation by DNA sequencing analysis. Patients 1, 2, and 3 all carried c.3061G\>A (p.E1021K), which is located in the kinase domain of p110δ and is a common pathogenic GOF mutation. These were all spontaneous mutations, and there was no variation in the same sites of their parents. The mutation site in Patient 4 was c.1100C\>T (p.S367L), which is found in the C2 domain of the p110δ protein. This mutation was inherited from the patient\'s father and is novel. Its pathogenicity is uncertain because the patient\'s father is asymptomatic (Figure [1](#ped412101-fig-0001){ref-type="fig"} and Table [1](#ped412101-tbl-0001){ref-type="table"}). Patient 4 also has a recessively inherited heterozygous *RAB27A* mutation (c.11G\>T) inherited from his mother. *RAB27A* is linked to PID‐associated hemophagocytic lymphohistiocytosis (HLH). However, because the patient\'s mother is asymptomatic, the mutation pathogenicity remains indefinite.

![Structure of the p110δ protein encoded by PIK3CD. The mutation sites involved in this study are shown in red while other previously reported mutations are shown in black.](PED4-2-257-g001){#ped412101-fig-0001}

###### 

Clinical diagnosis and mutation analysis of four patients with *PIK3CD* mutations

  Patient   Diagnosis    Mutation site          Type           Origin        New variation   Pathogenicity
  --------- ------------ ---------------------- -------------- ------------- --------------- -------------------
  1         CAEBV/APDS   c.3061G\>A, p.E1021K   Heterozygous   Spontaneous   No              Pathogenic, Known
  2         APDS         c.3061G\>A, p.E1021K   Heterozygous   Spontaneous   No              Pathogenic, Known
  3         CAEBV/APDS   c.3061G\>A, p.E1021K   Heterozygous   Spontaneous   No              Pathogenic, Known
  4         EBV‐HLH      c.1100C\>T, p.S367L    Heterozygous   Father        Yes             Uncertain

CAEBV, chronic active Epstein‐Barr virus; APDS, activated PI3K δ syndrome; EBV‐HLH, Epstein‐Barr virus‐associated hemophagocytic lymphohistiocytosis
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Clinical features {#ped412101-sec-0004}
-----------------

Patient 1, a boy aged 8 years and 4 months, presented with persistent lymphadenopathy and splenomegaly accompanied by recurrent fever for more than 3 months. He had been diagnosed with infectious mononucleosis, and was administered ganciclovir and dexamethasone which relieved his symptoms. However, he relapsed many times after stopping the medication and his condition persisted. Our physical and laboratory examination revealed greatly enlarged submaxillary lymph nodes, while hepatosplenomegaly and multiple abnormal lymph nodes in the abdomen and pelvis were detected by ultrasonography (Table [2](#ped412101-tbl-0002){ref-type="table"}). The patient had no history of pneumonia. Routine blood testing showed a decreased complete blood cell count. The peripheral blood Epstein Barr virus (EBV) antibody profile indicated a reactivation of EBV infection, and the EBV DNA load in the plasma was increased to 2.39 × 10^4^ copies/mL, which was sustained at a high level during the clinical course (Table [3](#ped412101-tbl-0003){ref-type="table"}). Bone marrow biopsy excluded the possibility of malignancy. A biopsy of the neck lymph nodes showed the expression of EBV‐encoded small RNAs, suggestive of a T cell lymphoproliferative disease. An immunological assay revealed a reversed CD4/CD8 T cell ratio (0.49%), and the absolute number of CD3^+^CD4^+^ T cells, CD3^+^CD8^+^ T cells, and CD3^--^CD19^+^ B ells was remarkably decreased. Additionally, the level of serum immunoglobulin (Ig)M was elevated (2.39 g/L) while IgA was decreased (Table [4](#ped412101-tbl-0004){ref-type="table"}).

###### 

Main clinical manifestations of four patients with *PIK3CD* mutations

  Characteristic                          Patient 1                           Patient 2           Patient 3         Patient 4
  --------------------------------------- ----------------------------------- ------------------- ----------------- -----------------------------------
  Age (year)/gender                       8.4/Male                            0.6/Female          1.7/Male          5.1/Male
  Recurrent fever                         Yes                                 Yes                 Yes               Yes
  Hepatomegaly(size, under the rib)       3 cm                                4 cm                3 cm              4 cm
  Splenomegaly(size, under the rib)       7 cm                                7.5 cm              9 cm              2 cm
  Lymphadenectasis(site, size)            submaxill, 3cm × 4cm                axilla, 3cm × 3cm   neck, 1cm × 1cm   ‐
  Lymph node biopsy(site, diagnosis)      Neck Tlymphoproliferative disease   ‐                   ‐                 Neck Tlymphoproliferative disease
  Recurrent pneumonia                     No                                  Yes                 Yes               Yes
  Respiratory infections                  No                                  Yes                 Yes               Yes
  Anemia                                  Yes                                 Yes                 Yes               Yes
  Rash                                    No                                  Yes                 No                No
  Developmental retardation               No                                  Yes                 No                No
  Susceptibility to EBV or CMV nfection   Yes                                 Yes                 Yes               Yes

EBV, Epstein‐Barr virus; CMV, cytomegalovirus.
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###### 

Routine blood test and etiology data of four patients with *PIK3CD* mutations

  Patient   Blood routine test (×10^9^/L)   Virus Infection                                                                            
  --------- ------------------------------- ----------------- ----- ------- ----- ----- -------------- ---- ---- ---- ---- ------ ---- ----
  1         2.48                            97                90    1.40    8     EBV   2.39 × 10^4^   \+   ‐    \+   \+   low    ‐    ‐
  2         16.20                           81                261   10.10   106   CMV   3.65 × 10^3^   ‐    ‐    ‐    ‐    ‐      \+   \+
  3         0.78                            63                75    0.27    64    EBV   3.89 × 10^4^   \+   ‐    \+   \+   high   ‐    ‐
  4         3.57                            104               30    0.42    31    EBV   1.76 × 10^6^   \+   \+   ‐    ‐    high   ‐    ‐

WBC, white blood cell; EBV, Epstein‐Barr virus; CMV, cytomegalovirus; CRP, C‐reactive protein; CA, capsid antigen; EA, early antigen; NA, nuclear antigen.

John Wiley & Sons, Ltd

###### 

Immunological data of four patients with *PIK3CD* mutations

  Patient   Lymphocyte subpopulation   Immunoglobulin (g/L)                                                                                       
  --------- -------------------------- ---------------------- ------ ------ ------ ------ ----- ------ ------ ------ ------ ------- ------ ------ -------
  1         410                        50.7                   120    14.8   240    30.4   70    8.5    320    39.5   0.49   17.70   2.39   0.55   8.95
  2         3400                       67.1                   1980   38.9   1550   30.4   610   11.9   1050   20.6   1.28   18.30   3.69   0.95   4.83
  3         280                        76.3                   190    50.3   90     24.4   6     4.6    64     17.2   2.06   2.49    4.13   0.07   1.56
  4         3160                       99.7                   57     1.8    3090   97.6   6     0.2    0      0      0.02   15.60   0.43   0.99   40.20

WBC, white blood cell; EBV, Epstein‐Barr virus; CMV, cytomegalovirus; CRP, C‐reactive protein; CA, capsid antigen; EA, early antigen; NA, nuclear antigen.

John Wiley & Sons, Ltd

Patient 2, a 6‐month‐old baby girl, presented with crying, hepatosplenomegaly, intermittent fever, and developmental retardation for more than 3 months. Our examination revealed a persistent pustule after vaccination on her left arm, and multiple red rashes over her entire body. Lagerhans cell histiocytosis was excluded after skin biopsy. Hepatosplenomegaly and multiple lymphadenopathy in the axilla were detected (Table [2](#ped412101-tbl-0002){ref-type="table"}). The patient had a history of repeated pneumonia, and severe pneumonia with respiratory failure was evident on examination. Her white blood cell count, neutrophils, and hemoglobin were greatly decreased (Table [3](#ped412101-tbl-0003){ref-type="table"}). Both EBV antibody and EBV DNA levels in the plasma were negative. However, cytomegalovirus (CMV)‐IgM and IgG in the peripheral blood were positive, and the CMV DNA concentration in the plasma was increased to 3650 copies/mL, suggestive of an active CMV infection. The subcutaneous tuberculin test was positive (++), and mycobacterium tuberculosis was found in the sputum. An immunological assay showed the absolute number and proportion of each lymphocyte subgroup were normal; however, the levels of both serum IgM (3.69 g/L) and IgG (18.3 g/L) were increased (Table [4](#ped412101-tbl-0004){ref-type="table"}).

Patient 3, a boy aged 1 year and 7 months, presented with hepatosplenomegaly and multiple cervical masses for unknown reasons 2 months after birth; a biopsy test at that time suggested inflammatory lesions. His condition persisted for 1 year and 5 months, during which routine blood tests repeatedly showed hypohemoglobin and thrombocytopenia. He had a history of repeated cough and pneumonia, and lung computed tomography (CT) indicated severe pneumonia. His whole blood cell count was greatly decreased (Table [3](#ped412101-tbl-0003){ref-type="table"}). Moreover, his bilirubin levels and reticulocytes were clearly increased and the Coombs test was positive. Initially, he was suspected to have autoimmune hemolytic anemia. However, retrospective analysis suggested this might be secondary to EBV infection because both the extractable nuclear antigen antibody and antinuclear antibody tests were negative. The EBV antibody profile of his peripheral blood was indicative of reactivation of EBV infection, and the EBV DNA load in the plasma was 3.89 × 10^4^ copies/mL, which was sustained at a high level during the clinical course (Table [3](#ped412101-tbl-0003){ref-type="table"}). An immunological assay revealed the absolute number of CD3^+^CD4^+^ T cells, CD3^+^CD8^+^ T cells, and CD3^--^CD19^+^ B cells was remarkably decreased, while serum IgM was increased (4.13 g/L) and IgG was decreased (2.49 g/L) (Table [4](#ped412101-tbl-0004){ref-type="table"}).

Patient 4, a boy aged 5 years and 1 month, presented with high fever and hepatosplenomegaly accompanied by a decrease in the complete blood count for 1 month. Our examination also revealed the above clinical manifestations. Blood biochemical testing revealed greatly increased levels of triglyceride (\> 3 mmol/L), sCD25 (\> 44 000 pg/mL), and ferritin (88 691 ng/mL), while fibrinogen (\< 1.5 g/L) and natural killer (NK) cell activity (14.44%) were remarkably reduced. The peripheral blood EBV antibody profile indicated a late initial infection of EBV, and the EBV DNA load in the plasma was 1.76 × 10^6^ copies/mL which was sustained at a high level during the clinical course. The patient was diagnosed with EBV‐associated HLH based on HLH diagnostic criteria. A biopsy of his cervical lymph node revealed an EBV‐related T lymphoproliferative disease, while flow cytometry of the bone marrow showed that 80.54% of mature T cells had an abnormal phenotype, suggestive of lymphoma. Cardiac and coronary artery ultrasound revealed bilateral ectasia of the coronary artery. An immunological assay revealed a marked increase in the number of CD3^+^ T and CD3^+^CD8^+^ T cells, while the number of CD3^+^CD4^+^ T cells and CD3^--^ CD19^+^ B cells was greatly decreased. However, the level of IgG was greatly elevated in a setting of a low number of B cells. This may be because the patient had received Ig supplementation when the titers were measured (Table [4](#ped412101-tbl-0004){ref-type="table"}).

Diagnosis and treatment {#ped412101-sec-0005}
-----------------------

All four cases presented with repeated fever, hepatosplenomegaly, and blood cell abnormalities as the initial manifestation. Patient 1 showed typical characteristics of chronic active Epstein‐Barr virus (CAEBV) infection with no definite reason during his clinical course, so was diagnosed with CAEBV. He received ganciclovir and pegaspargase, liposomal doxorubicin, etoposide, and methylprednisolone (L‐DEP) chemotherapy, but had an unfavorable prognosis. Subsequently, he was detected with a pathogenic *PIK3CD* mutation, and was finally diagnosed with PASLI. Eventually, he underwent haploid allogeneic hematopoietic stem cell transplantation (allo‐HSCT) and has remained well 1 year later.

Patient 2 was diagnosed with PASLI and pulmonary tuberculosis. She was treated with ganciclovir, gammaglobulin, and rapamycin for immunodeficiency disease; she was also given rifampicin and isoniazid against tuberculosis infection. During her follow‐up, hepatosplenomegaly, lymphadenopathy, and respiratory infections were greatly improved.

Patient 3 had a chronic repeated condition, and was also diagnosed with CAEBV during the early course. For financial reasons, he only received ganciclovir and dexamethasone therapy. This improved his hepatosplenomegaly and lymphadenopathy, but he developed recurrent pneumonia during the clinical course. He was diagnosed with PASLI following the identification of a pathogenic *PIK3CD* mutation, and received regular oral gammaglobulin infusion and rapamycin. This improved his hepatosplenomegaly, lymphadenopathy, and lung lesions, but his condition was not well controlled because his interruption of treatment for some reason.

Patient 4 was diagnosed with EBV‐related T lymphoproliferative disease complicated by HLH. The HLH 2004 chemotherapy regimen was initially applied, but his situation did not improve. He then received L‐DEP regimen treatment but unfortunately relapsed. Finally, he underwent allo‐HSCT and achieved complete remission.

DISCUSSION {#ped412101-sec-0006}
==========

PI3Kδ, a class 1 PI3K isoform, is a heterodimer comprising a p110δ catalytic subunit and a p85 regulatory subunit. PI3Kδ is expressed predominantly in leukocytes and plays an important role in their proliferation, survival, and activation. *PIK3CD* encodes the catalytic subunit p110δ, a protein of 1044 amino acids with at least five domains identified by structure and function: an adaptor‐binding domain (ABD), a Ras GTPase binding domain (RBD), a C2 domain, a helical domain, and a lipid kinase domain with amino (N) and carboxyl (C) side lobes (Figure [1](#ped412101-fig-0001){ref-type="fig"}). Heterozygous GOF variants in *PIK3CD* can enhance the catalytic activity of p110δ and subsequently increase PI3Kδ basal intracellular signaling in lymphocytes. Overactivation of PI3Kδ and its downstream signaling can lead to a range of B and T cell developmental and functional defects that compromise host defense, leading to clinical manifestations of immunodeficiency.[1](#ped412101-bib-0001){ref-type="ref"}, [6](#ped412101-bib-0006){ref-type="ref"}

A total of nine pathogenic GOF variants have been identified in *PIK3CD* across a range of continents and ethnicities: N333K,[6](#ped412101-bib-0006){ref-type="ref"} R405C,[7](#ped412101-bib-0007){ref-type="ref"} and C416R[8](#ped412101-bib-0008){ref-type="ref"} in the C domain; E81K[8](#ped412101-bib-0008){ref-type="ref"} in the ABD domain and G124D[8](#ped412101-bib-0008){ref-type="ref"} between two helices in the ABD--RBD linker; E525K and E525A[9](#ped412101-bib-0009){ref-type="ref"} in the helical domain; and R929C[10](#ped412101-bib-0010){ref-type="ref"} and E1021k[11](#ped412101-bib-0011){ref-type="ref"} in the C‐terminal lobe of the kinase domain, of which E1021k appears to be a mutation hotspot (Figure [1](#ped412101-fig-0001){ref-type="fig"}). These variants cause overactivation of PI3Kδ and the subsequent downstream pathway in two ways depending on the mutation site: they either obstruct binding of the p110δ subunit with the regulatory p85α subunit domain to reduce p85α regulation, such as the E525K and N334K mutation, or they directly enhance recruitment of p110δ to the plasma membrane and increase its catalytic activity, such as the E1021K mutation.[6](#ped412101-bib-0006){ref-type="ref"}, [12](#ped412101-bib-0012){ref-type="ref"}, [13](#ped412101-bib-0013){ref-type="ref"}

PASLI is an autosomal dominant primary immunodeficiency caused by GOF mutations in *PIK3CD*. It often occurs in young children and is characterized by recurrent sinopulmonary infections with associated lung damage, susceptibility to EBV and cytomegalovirus, hepatosplenomegaly, and lymphoproliferative disease. The main immunologic features are decreased numbers of CD4^+^ T cells and B cells especially naive CD4^+^ T cells and naive B cells, increased numbers of transitional B cells, increased IgM levels, and/or decreased IgG.[14](#ped412101-bib-0014){ref-type="ref"}Few cases of PASLI have been reported worldwide and there are no unified clinical diagnosis criteria, so the diagnosis depends mainly on genetic testing.

In this study, we describe three children with the same heterozygous GOF mutation (E1021K) of *PIK3CD* diagnosed with PASLI. The clinical characteristics of the three children were quite variable despite carrying the same pathogenic mutation, which is similar to the findings of a large patient cohort study report.[14](#ped412101-bib-0014){ref-type="ref"} It is worth noting that both Patient 1 and Patient 3 mainly manifested as CAEBV during their clinical course. Indeed, both were diagnosed with CAEBV until the results of genetic testing were obtained, suggesting that CAEBV may be one of the clinical manifestations of PASLI in some cases. Furthermore, the etiology of CAEBV is unknown and this is the first report of *PIK3CD* mutations in CAEBV, which implies that immune deficiencies caused by *PIK3CD* mutations are likely to be associated with the pathogenesis of CAEBV. Several cases have been reported in which mutations of *STXBP2*,[15](#ped412101-bib-0015){ref-type="ref"} *PRF1*,[16](#ped412101-bib-0016){ref-type="ref"} *JAK3* [17](#ped412101-bib-0017){ref-type="ref"} and *GATA2* [18](#ped412101-bib-0018){ref-type="ref"} lead to CAEBV. Similar to *PIK3CD*, these genes are essential for regulating lymphocyte activation, proliferation, or function, and variants of these genes are closely associated with many primary immunodeficiency diseases. Hartman et al reported that the *PIK3CD* E1021K mutation could lead to PSC, the common complication of high IgM syndrome, which is also a primary immunodeficiency.[5](#ped412101-bib-0005){ref-type="ref"} Taken together, these findings indicated that although most variations of *PIK3CD* are associated with PASLI, the immune deficiency manifestations caused by *PIK3CD* mutations may be diverse, and their genetic and immunological mechanisms deserve further investigation.

We also reported a patient (Patient 4) carrying a new heterozygous variant (S367L) of *PIK3CD*. He had similar clinical manifestations to PASLI, including hematocytopenia, hepatosplenomegaly, EBV virus susceptibility, and lymphoproliferation. However, because this mutation was inherited from his asymptomatic father, it was not sufficient to diagnose PASLI. Compared with the other three children in our study with known pathogenic mutations, the condition of Patient 4 was urgent and progressed rapidly. He also presented with distinct characteristics of T lymphoproliferative disease. Therefore, he was diagnosed with EBV‐associated T lymphoproliferative disease combined with HLH. Interestingly, we noticed that the NK cell activity of Patient 4 was reduced in multiple examinations. Moreover, because he was more likely to relapse after chemotherapy, he eventually underwent hematopoietic stem cell transplantation. These findings suggest the possibility of genetic abnormality in this patient. Ultimately, however, only heterozygous mutations of *PIK3CD* (p.S367L) and *RAB27A* (p.G4V) were detected, which were inherited from his father and mother, respectively. Although both mutations were predicted to be deleterious by protein structure prediction software, neither of his parents showed similar symptoms to him.

With increasing awareness of HLH, more studies have suggested that it has digenic inheritance. As such, the combination of concurrent partial defects in two or more genes gives rise to a clinical phenotype, whereas a heterozygous state in either of the genes alone results in a less severe phenotype or none at all.[19](#ped412101-bib-0019){ref-type="ref"}, [20](#ped412101-bib-0020){ref-type="ref"}, [21](#ped412101-bib-0021){ref-type="ref"} Therefore, in this case, Patient 4 may have carried two hypomorphic genetic defects in *PIK3CD* and *RAB27A*, which could have contributed in the development of HLH when he was challenged by viral infection and other stresses. This may also explain the fact that neither parent had relevant clinical manifestations despite carrying one of the same mutations. We hope that this case report will provide clinicians with an insight into possible pathogenic mechanisms of this mutation, although further research is required to define the functional effects of these genetic alterations.
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